

React with Speed.
React with Agility.
React with Confidence.



React™ 68

Catheter

Medtronic
Further. Together

STROKE IS NEVER EXPECTED,
BUT KNOWING HOW TO **REACT**,
HAS THE POWER TO CHANGE LIVES.


NAVIGABILITY
OF A COIL¹



PUSHABILITY
OF A BRAID¹



DURABILITY
OF NITINOL¹



COMPATIBLE WITH
SOLITAIRE™ PLATINUM¹



- Large 0.068 Inner Diameter Lumen¹
- Atraumatic Beveled Distal Tip¹

FEATURING


COBRA
COIL + BRAID

TECHNOLOGY¹

An overlapping coil +
braid construction¹



PRODUCT FEATURES¹



REACT™ 68 CATHETER ORDERING INFORMATION²

Product Catalog Number	ID	MAX OD	Working Length		
REACT-68	0.068"	0.083"	132cm		

BUNDLE ORDERING INFORMATION

Product Catalog Number	Riptide™ Aspiration Pump	React™ 68 Catheter	Riptide™ Aspiration Tubing	Riptide™ Collection Canister	Solitaire™ Platinum
RBUNDLE-68	Qty. 1	Qty. 3	Qty. 3	Qty. 3	
RIPTIDE-68		Qty. 1	Qty. 1	Qty. 1	
STAT-6-40-68		Qty. 1	Qty. 1	Qty. 1	Qty. 1 6x40
STAT-4-40-68		Qty. 1	Qty. 1	Qty. 1	Qty. 1 4x40
REACT-6-40		Qty. 1			Qty. 1 6x40
REACT-4-40		Qty. 1			Qty. 1 4x40

CAUTION: Federal (USA) law restricts this device to sale distribution and use by or on order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

The React™ 68 Catheter is indicated for the introduction of interventional devices into the peri-pheral and neuro vasculature.

The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neuro-vasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

Medtronic

9775 Toledo Way
Irvine, CA 92618
USA
Tel 877.526.7890
Fax 763.526.7888

medtronic.com

1. All claims have been substantiated and data is on file TR-NV15399 Rev A.

2. DWGSREACT-68 Rev C Design Specification

© 2018 Medtronic. All right reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. DC00088276 Rev A OCT/2018